Effect of Early Amiodarone Use on Warfarin Sensitivity, Blood Product Use, and Bleeding in Patients With a Left Ventricular Assist Device

Curr Probl Cardiol. 2023 Oct;48(10):101801. doi: 10.1016/j.cpcardiol.2023.101801. Epub 2023 May 18.

Abstract

Data are scarce on the effect of amiodarone on warfarin sensitivity and related outcomes after placement of a left ventricular assist device (VAD). This retrospective study compared 30-day outcomes between patients on amiodarone vs no amiodarone after VAD implant. After exclusions, 220 patients received amiodarone and 136 patients did not. Compared to the no amiodarone group, the amiodarone group had a higher warfarin dosing index (0.53 [0.39, 0.79] vs 0.46 [0.34, 0.63]; P = 0.003), incidence of INR ≥ 4 (40.5 vs 23.5%; P = 0.001), incidence of bleeding (24.1 vs 14%; P = 0.021), and use of INR reversal agents (14.5 vs 2.9%, P ≤ 0.001). Amiodarone was associated with bleeding (OR, 1.95; 95% CI, 1.10-3.47; P = 0.022), but not after adjusting for age, estimated glomerular filtration rate, and platelet count (OR, 1.67; 95% CI, 0.92-3.03; P = 0.089). After VAD implant, amiodarone was associated with increased warfarin sensitivity and administration of INR reversal agents.

Publication types

  • Review

MeSH terms

  • Amiodarone* / adverse effects
  • Anti-Arrhythmia Agents
  • Anticoagulants / adverse effects
  • Heart-Assist Devices* / adverse effects
  • Hemorrhage / chemically induced
  • Humans
  • Retrospective Studies
  • Warfarin / adverse effects

Substances

  • Amiodarone
  • Anti-Arrhythmia Agents
  • Anticoagulants
  • Warfarin

Supplementary concepts

  • Warfarin Sensitivity